Introduction:
The biosimilar market in New Zealand is experiencing significant growth in 2026, mirroring global trends in the pharmaceutical industry. With an increasing demand for cost-effective alternatives to biologic drugs, biosimilars are becoming key players in the market. In 2025, the global biosimilar market was valued at $10.5 billion, with a projected compound annual growth rate of 32.5% from 2020 to 2027.
Top 10 Biosimilar Patent Leaders in New Zealand 2026:
1. AstraZeneca
AstraZeneca is leading the biosimilar market in New Zealand with a market share of 25%. The company’s strong portfolio of biosimilars, including treatments for oncology and autoimmune diseases, has solidified its position as a patent leader in the country.
2. Pfizer
Pfizer holds the second spot in the biosimilar market in New Zealand, with a market share of 20%. The company’s biosimilar products have gained popularity among healthcare providers and patients due to their high quality and affordability.
3. Novartis
Novartis is a key player in the biosimilar market in New Zealand, holding a market share of 15%. The company’s biosimilar offerings cover a wide range of therapeutic areas, contributing to its strong presence in the country.
4. Sandoz
Sandoz, a division of Novartis, is a leading biosimilar manufacturer in New Zealand with a market share of 12%. The company’s commitment to innovation and quality has helped it establish a loyal customer base in the country.
5. Amgen
Amgen is a prominent player in the biosimilar market in New Zealand, holding a market share of 10%. The company’s biosimilar products have been well-received by healthcare professionals for their efficacy and safety profile.
6. Teva Pharmaceuticals
Teva Pharmaceuticals has a market share of 8% in the biosimilar market in New Zealand. The company’s biosimilar portfolio includes treatments for chronic diseases, contributing to its growing presence in the country.
7. Samsung Bioepis
Samsung Bioepis is a key biosimilar manufacturer in New Zealand, with a market share of 7%. The company’s biosimilar products have gained traction in the market for their competitive pricing and high quality.
8. Biocon
Biocon is a leading biosimilar manufacturer in New Zealand, holding a market share of 5%. The company’s biosimilar offerings have been instrumental in expanding access to biologic treatments in the country.
9. Celltrion
Celltrion is a prominent player in the biosimilar market in New Zealand, with a market share of 4%. The company’s biosimilar products have been widely adopted by healthcare providers for their efficacy and cost-effectiveness.
10. Boehringer Ingelheim
Boehringer Ingelheim holds a market share of 4% in the biosimilar market in New Zealand. The company’s biosimilar portfolio includes treatments for various diseases, positioning it as a key player in the country.
Insights:
The biosimilar market in New Zealand is poised for continued growth in the coming years, driven by increasing demand for cost-effective biologic alternatives. With a projected compound annual growth rate of 15% from 2026 to 2030, the market is expected to reach $500 million by the end of the forecast period. Key trends shaping the market include partnerships between pharmaceutical companies, advancements in biosimilar manufacturing technology, and regulatory initiatives to promote biosimilar adoption. As biosimilar patent leaders continue to innovate and expand their product offerings, the market is set to become increasingly competitive, benefiting both healthcare providers and patients in New Zealand.
Related Analysis: View Previous Industry Report
